#USA #Mount Pleasant #Epidermolysis Bullosa #Paradigm Therapeutics #Zorblesia™

Paradigm Therapeutics Receives 2026 Prix Galien USA Nomination

MOUNT PLEASANT, S.C., October 13, 2026 - Paradigm Therapeutics, Inc. has made headlines by being nominated for the prestigious 2026 Prix Galien USA 'Best Start-Up' Award for its groundbreaking product, SD-101 (Zorblesia™). This topical therapy is designed specifically to treat the entire skin surface of patients suffering from Epidermolysis Bullosa (EB), a rare and debilitating genetic disorder characterized by fragile skin that blisters and tears easily.

This nomination marks a significant moment as it is the second consecutive year Paradigm has been recognized in this category. The Prix Galien USA awards are often referred to as the 'Nobel Prize of biopharmaceutical research', and they celebrate innovations that care for significant unmet medical needs. The award ceremony is set to take place on October 29, 2026, at the American Museum of Natural History in New York City.

Commitment to Rare Diseases

Paradigm Therapeutics is a clinical-stage biopharmaceutical company devoted to transforming the treatment landscape for rare diseases, particularly focusing on EB. Dr. Robert Ryan, the CEO, expressed pride in the company's consistent progress, thanking the dedicated team for their commitment to advancing treatment options for the three main EB subtypes: Simplex, Dystrophic, and Junctional.

“The nomination reflects our significant advancements in EB care,” Dr. Ryan stated. “We are dedicated to developing therapies that treat the skin comprehensively for both pediatric and adult patients suffering from this devastating condition.”

What is Epidermolysis Bullosa?

Epidermolysis Bullosa is a genetic condition affecting approximately 20,000 people in the United States that leads to serious skin complications. Patients often present with severe blistering and open wounds, primarily due to the fragility of their skin. The disease can drastically impact a person’s quality of life, with wounds occurring from minor contact and requiring extensive care.

Currently, no approved therapies exist that adequately treat the entire surface of the skin across all EB subtypes, highlighting the importance of Paradigm's work in this arena.

Introducing SD-101 (Zorblesia™)

SD-101 (Zorblesia™) has already been recognized as a potential game-changer in EB treatment. This topical cream stands out as the first EB therapy to obtain a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). Furthermore, it also holds the Rare Pediatric Disease and Orphan Drug designations from the FDA, as well as a similar designation from the European Commission.

In clinical trials involving 217 pediatric and adult patients, SD-101 demonstrated promising results, providing a viable treatment for the severe skin lesions associated with EB. The therapy requires no special handling, can be stored at room temperature, and was well-received in studies where it was applied daily over three months, including to very young patients as young as 28 days.

Paradigm's Vision for the Future

The vision for Paradigm Therapeutics extends beyond being a leading innovator in EB treatment. They aspire to provide SD-101 globally, working diligently with potential partners to expedite its availability. With a strong scientific foundation and a commitment to patient care, Paradigm proves to be a beacon of hope for those affected by EB.

In summary, Paradigm Therapeutics, through its innovative approach and dedication, stands at the forefront of medical advancements in treating Epidermolysis Bullosa. As they aim for regulatory approvals and further developments, their nomination for the 2026 Prix Galien USA acknowledges not only their hard work but also the urgent need for improved treatments for rare diseases. As we await the award ceremony, many in the healthcare community will watch closely, hopeful for the next steps in transforming EB care.